ENANTYUM ® Dexketoprofen
ENANTYUM ® is a drug based on Dexketoprofen salt of trometamol
THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugsIndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications ENANTYUM ® Dexketoprofen
ENANTYUM ® is indicated in the short-term symptomatological treatment of mild to moderate pain of various kinds, including dysmenorrhoea.
Mechanism of action ENANTYUM ® Dexketoprofen
ENANTYUM ®, a drug belonging to the non-steroidal anti-inflammatory category, has dexketoprofen as an active ingredient, a derivative of propionic acid and successor to the more well-known ibuprofen, which distinguishes itself not only for its chemical structure but also for its pharmacokinetic properties, characterized by the more rapid intestinal absorption profile which allows the plasma peak to be reached in just 30 minutes.
The last phases of distribution and excretion and the pharmacodynamic characteristics, such as to allow the aforementioned active ingredient to carry out an analgesic, anti-inflammatory and antipyretic action, remain unchanged.
All these therapeutic properties are guaranteed by the inhibitory action exerted by dexketoprofen against cyclooxygenases, intracellular enzymes involved in the metabolism of arachidonic acid and responsible for the synthesis of chemical mediators with pro-inflammatory activity such as prostaglandins and prostacyclins and at the same time from inducing action against lipoxygenases, able to mediate the expression of molecules with anti-inflammatory activity such as lipoxins.
The inhibitory action therefore results in a reduction of the inflammatory insult, of the possible edema present and of the pain transmission.
Studies carried out and clinical efficacy
1. THE EFFICACY OF DEXKETOPROPHEN IN THE POST-OPERATIVE PAIN
Agri. 2011 Oct; 23 (4): 153-9.
Study demonstrating how dexketoprofen intake can be effective in the treatment of post-operative pain, thus ensuring a reduction in the doses of morphine normally used. Paracetamol has not shown the same effect.
2. IBUPROFENE + LIDOCAINE IN LOCAL ANESTHESIA
J Int Med Res. 2011; 39 (5): 1923-31.
Work demonstrating how the addition of dexketoprofen to lidocaine in local anesthesia can optimize anesthetic action and also reduce post-operative pain, without clinically relevant side effects.
3. IBUPROFENE AND RABDOMIOLYSIS
Int Urol Nephrol. 2011 May 7.
Case report that reports the appearance of acute renal failure due to a massive rhabdomyolysis induced by dexketoprofen, taken by a 70-year-old patient to treat a common cold. These studies highlight the importance of medical supervision in the treatment of NSAIDs
Method of use and dosage
Tablets 12.5 - 25 mg dexketoprofen:
Generally the intake of 50 mg daily of dexketoprofen, divided into several administrations, is sufficient to guarantee an effective remission of the complained symptoms, although in some cases, it could be necessary to raise the doses up to a maximum of 75 mg daily.
An adjustment of the doses used may be required in elderly patients or those with hepatic and renal insufficiency.
Warnings ENANTYUM ® Dexketoprofen
Although ENANTYUM ® can be sold without a prescription, you should consult your doctor before taking this medicine.
The different side effects affecting the gastrointestinal mucosa, the liver, the kidney and the cardiovascular system described following the use of dexketoprofen, suggest the need to consult your doctor, who should monitor the state of functionality of the aforementioned organs.
In order to minimize the incidence of side effects, it would be appropriate to start therapy with the minimum dose of dexketoprofen necessary to guarantee a prompt remission of the symptoms.
If there are signs of toxicity or side effects related to the use of this drug, the patient should immediately contact his doctor and decide if necessary to stop taking ENANTYUM ®.
PREGNANCY AND BREASTFEEDING
The use of dexketoprofen is not recommended, as is that of all other non-steroidal anti-inflammatory drugs, in pregnancy, given the inhibitory effect on prostaglandin synthesis.
This inhibition plays a key role in the genesis of embryonic and fetal damage, I note the role of prostaglandins in guaranteeing the process of cell proliferation and differentiation, as demonstrated by various studies in which the high concentration of NSAID blood is associated with the appearance of fetal malformations and unwanted abortions.
We do not recommend taking ENANTYUM ® even during the next breastfeeding period, given the ability of dexketoprofen to be excreted in breast milk.
The use of dexketoprofen, as well as that of most other non-steroidal anti-inflammatory drugs, is often undermined by potential drug interactions capable of altering the therapeutic characteristics of the drug and increasing its potential side effects.
Particular attention should be paid to the simultaneous assumption of:
- Oral anticoagulants and serotonin reuptake inhibitors, given the increased risk of bleeding;
- Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporine given the side effects, mainly concentrated at the renal level;
- Non-steroidal anti-inflammatory drugs and corticosteroids due to the increased incidence of gastritis and peptic ulcers;
- Antibiotics due to the reduction of therapeutic efficacy;
- Sulfonylureas due to an altered glycemic control, exerted by the hypoglycemic effect of dexketoprofen.
Contraindications ENANTYUM ® Dexketoprofen
Taking ENANTYUM ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, hypersensitive to acetylsalicylic acid and other analgesics, suffering from asthma, nasal polyposis, liver failure, renal to cardiac, intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same conditions.
Undesirable effects - Side effects
Different clinical trials and careful post-marketing monitoring have allowed us to characterize the side effects associated with dexketoprofen therapy.
More precisely, this therapy was associated with the appearance of:
- Nausea, abdominal pain, vomiting, diarrhea, dyspepsia and rarely gastritis and peptic ulcers;
- Insomnia, headache, drowsiness and dizziness;
- Skin rashes, hives and hypersensitivity dermatological reactions.
More rarely, and generally following long-lasting treatments or performed at particularly high doses, the appearance of renal, hepatic and cardiovascular diseases has been observed.
ENANTYUM ® can be sold without a prescription.